📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. (2017)

First Author: Stein EM

Attributed to: Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Acute Myelodi Leukaemia (and Solid Tumours). funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood-2017-04-779405

PubMed Identifier: 28588020

Publication URI: http://europepmc.org/abstract/MED/28588020

Type: Journal Article/Review

Volume: 130

Parent Publication: Blood

Issue: 6

ISSN: 0006-4971